Clinical Research Directory
Browse clinical research sites, groups, and studies.
Summary
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).
Official title: Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) Patients and sJIA Patients (REASSURE)
Key Details
Gender
All
Age Range
2 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
25
Start Date
2025-03-29
Completion Date
2028-09-30
Last Updated
2025-12-30
Healthy Volunteers
No
Conditions
Interventions
Ilaris
Prospective observational study. There is no treatment allocation.
Locations (1)
Novartis Investigative Site
Seoul, South Korea